Abstract: SA-PO1177
Bridging Cardiorenal Care Across Borders: Comparative Clinical Outcomes and Key Features of Interdisciplinary Clinics in Mexico and the United Kingdom
Session Information
- CKD: SGLT2 Inhibitors and GLP-1 RAs for Kidney Health
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- Gomez Johnson, Victor Hugo, Instituto Nacional de Cardiologia Ignacio Chavez, State of Mexico, Méx., Mexico
- Rufus-Toye, Remi Mohan, St George's University Hospitals NHS Foundation Trust, London, England, United Kingdom
- Higton, Katy, St George's University Hospitals NHS Foundation Trust, London, England, United Kingdom
- Gil, Salvador Lopez, Instituto Nacional de Cardiologia Ignacio Chavez, State of Mexico, Méx., Mexico
- Jordan-Rios, Antonio, Instituto Nacional de Cardiologia Ignacio Chavez, State of Mexico, Méx., Mexico
- Hernandez Badillo, Luis E, Instituto Nacional de Cardiologia Ignacio Chavez, State of Mexico, Méx., Mexico
- Bautista Reyes, Edgar, Instituto Nacional de Cardiologia Ignacio Chavez, State of Mexico, Méx., Mexico
- Madero, Magdalena, Instituto Nacional de Cardiologia Ignacio Chavez, State of Mexico, Méx., Mexico
- Banerjee, Debasish, St George's University Hospitals NHS Foundation Trust, London, England, United Kingdom
Background
Interdisciplinary cardiorenal clinics are rare, and cross-country comparisons are lacking. This study aims to provide the first comparative analysis of interdisciplinary clinics in Mexico and the United Kingdom (UK).
Methods
This prospective cohort study uses independently collected data from cardiorenal clinics in Mexico and the UK (June 2024–present) to report baseline characteristics and assess the implementation of guideline-directed medical therapy (GDMT).
Results
At baseline, both cohorts had similar eGFR and comparable prevalence of diabetes mellitus and ischemic heart disease. However, the Mexican cohort was younger, had a higher prevalence of HFrEF, and higher NT-proBNP levels (Table 1). Use of ARNi/ACEi/ARB, beta-blockers, MRA, SGLT2i, and all four GDMT at baseline was 75%, 76%, 38%, 70%, and 30% in the UK cohort, and 71%, 75%, 53%, 77%, and 37% in the Mexican cohort. At follow up, respective use increased to 84%, 84%, 46%, 84%, and 51% in the UK, and 80%, 91%, 72%, 98%, and 51% in Mexico (Tables 2 and 3). Serum electrolytes and eGFR remained unchanged at baseline and follow up in both cohorts. (table 4 and 5)
Conclusion
This study shows that, despite center-specific limitations, GDMT can be implemented and intensified in patients with heart failure and chronic kidney disease. Continued use of GDMT did not impair renal function or serum electrolytes, highlighting the essential role of interdisciplinary cardiorenal clinics in safely optimizing care for this high-risk population.